According to PR Newswire's report on January 7th, the US pharmaceutical company Qnovia, Inc. announced that the first patient in the US has been administered with RespiRx™ nicotine inhaler (QN-01) in the phase I clinical trial as a smoking cessation therapy.
RespiRx™ is a drug delivery device that combines a portable handheld nebulizer with a metered dose medication cartridge to administer medication in aerosol form.
Qnovia's CEO Brian Quigley stated,
We are pleased to have administered medication to the first patient in our first clinical trial, aimed at addressing global cigarette use issues and innovating smoking cessation treatment. Overall, we believe today's news represents Qnovia's official transformation into a biopharmaceutical company, developing the next generation of smoking cessation therapies.
This clinical trial aims to address the need for effective and easily accessible smoking cessation therapy, evaluating the pharmacokinetics, safety, and tolerability of RespiRx™. The trial is a randomized crossover open-label study, including up to 24 healthy adult smokers. The primary endpoints are the maximum concentration, AUC 0-30, and Tmax of plasma nicotine after baseline adjustment. The study is being conducted by Vince Clinical Research Company in Overland Park.
The company expects to release the first phase trial data of the RespiRx™ nicotine inhaler in the second quarter of 2025, and submit a clinical trial application in the UK in the second half of 2025.
Qnovia, Inc. is a US-based platform medical technology and pharmaceutical company founded by Mario Danek in 2018. It focuses on developing and commercializing proprietary inhalation device technology to improve patient outcomes. Its flagship product, RespiRx™, is a medication-grade inhalation drug delivery system based on a cartridge, designed to help smokers quit smoking.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
